Estradiol acetate

Estradiol acetate

Systematic (IUPAC) name
(17β)-3-hydroxyestra-1,3,5(10)-trien-17-yl acetate
Clinical data
Legal status	℞ (Prescription only)
Routes of administration	Oral, vaginal (ring)
Identifiers
CAS Number	1743-60-8
ATC code	None
PubChem	CID: 6852404
ChemSpider	5254726
Chemical data
Formula	C20H26O3
Molecular mass	314.419 g/mol
SMILES O=C(O[C@H]3CC[C@H]4[C@H]2[C@@H](c1ccc(O)cc1CC2)CC[C@]34C)C
InChI InChI=1S/C20H26O3/c1-12(21)23-19-8-7-18-17-5-3-13-11-14(22)4-6-15(13)16(17)9-10-20(18,19)2/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1 Key:QAHOQNJVHDHYRN-SLHNCBLASA-N

Estradiol acetate (INN, USAN, BAN; brand names Femtrace, Femring, Menoring) is a synthetic ester, specifically the 3-O-acetyl ester, of the natural estrogen, estradiol. It is relatively recent to the market, having been first approved in a vaginal ring formulation as Menoring in the United Kingdom in 2001, followed by another vaginal ring formulation as Femring in the United States in 2003, and finally as an oral preparation as Femtrace in the United States in 2004. It is used as a form of hormone replacement therapy to treat and prevent symptoms of menopause such as osteoporosis in postmenopausal women.

The Women's Health Initiative studies report increased health risks for postmenopausal women when using unopposed estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

• Estrogen ester